Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: €29.8

Transcript 10-Q8-K

Key Points

Positve

Crinetics Pharmaceuticals Inc (CRNX) successfully launched Palsonify, with significant progress made in the initial 31 weekdays since approval.
The company has a strong financial position with $1.1 billion in cash equivalents and investments, providing a runway to fund operations into 2029.
Palsonify is receiving positive feedback from both community endocrinologists and major pituitary centers, indicating strong market acceptance.
The company is executing a comprehensive strategy to expand the acromegaly market, including targeting treatment-naive patients and those lost to follow-up.
Crinetics Pharmaceuticals Inc (CRNX) has a robust pipeline with multiple late-stage programs advancing, including trials for carcinoid syndrome and congenital adrenal hyperplasia (CAH).

Negative

The company did not recognize any revenue related to the launch of Palsonify in the third quarter due to the timing of approval.
Research and development expenses increased to $90.5 million in the third quarter, reflecting higher costs associated with clinical programs.
There are delays in the timelines for the SST3 agonist program for ADPKD and the TSH candidate for Graves' disease due to identified weaknesses.
The company is facing challenges in transitioning patients from open-label extension studies to commercial supplies, with timelines extending into 2026.
Crinetics Pharmaceuticals Inc (CRNX) is not providing regular updates on the timing of preclinical programs until those programs dose their first patient in a phase 1 study.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRNX.OQ - Crinetics Pharmaceuticals Inc
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Chretics Pharmaceuticals 3rd quarter 2025 financial results conference call.

At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session.

I'd now like to turn the call over to Gayatri Dewaka, head of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the 3rd quarter 2025 results. Today on the call, we have Dr. Scott Struthers,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.